Concord Biotech (CONCORDBIO) Share Price Falls 7.65% to Rs 1,272.9 on 28 October 2026
- October 28, 2026
- Posted by: Kunal Singla
- Category: News
The Concord Biotech Share Price stood at Rs 1,272.9 on 28 October 2026, down 7.65% from the previous close of Rs 1,378.35, a fall of Rs 105.45 per share. The Mid Cap company, listed under the symbol CONCORDBIO, carries a market capitalisation of Rs 13,666.01 crore.
This share price fall matters because the move is large for a single session and the stock sits in the Pharmaceuticals & Drugs industry, where the benchmark covers 199 companies. Concord Biotech reports a P/E ratio of 52.36 and a P/B ratio of 6.95, against industry medians of 30.74 and 2.71. The sections below set out what happened, the fundamentals, the sector benchmark and the peer picture, so readers can follow the Concord Biotech Stock News in one place.
What should investors monitor next? The Concord Biotech Share Price Today relative to the previous close, the valuation gap against the industry benchmark, and any company announcement that explains the decline. Univest tracks all three on its stock page.
Concord Biotech (CONCORDBIO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,272.9 |
| Previous Close | Rs 1,378.35 |
| Today's Move | -Rs 105.45 (-7.65%) |
| Open | Rs 1,339.95 |
| High | Rs 1,339.95 |
| Low | Rs 1,265.3 |
| Market Capitalisation | Rs 13,666.01 crore |
| Market Cap Category | Mid Cap |
The Concord Biotech Share Price Today shows a clear single-session decline. The stock last traded at Rs 1,272.9 against a previous close of Rs 1,378.35, which works out to a day change of -Rs 105.45 or -7.65%. This is the latest session only, so the move should not be read as part of a longer streak.
The stock opened at Rs 1,339.95, which is also the day high, and has since touched a day low of Rs 1,265.3. As of 28 October 2026 at 10:23:15 AM IST, the Concord Biotech Share Price sits at Rs 1,272.9, inside that range of Rs 1,265.3 to Rs 1,339.95.
The market capitalisation of Rs 13,666.01 crore places the company in the Mid Cap category. That is above the Pharmaceuticals & Drugs industry median market capitalisation of Rs 696.43 crore, and above the industry average of Rs 13,492.66 crore. The Concord Biotech Share Price Fall therefore comes from a company whose size can be judged directly against the benchmark. With price action covered, the next step is to check how the fundamentals frame this move.
Why Concord Biotech (CONCORDBIO) May Be Moving Today
Concord Biotech (CONCORDBIO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 13,666.01 crore |
| P/E Ratio | 52.36x |
| P/B Ratio | 6.95x |
| ROE | 13.54% |
| ROCE | 18.04% |
| EPS | Rs 26.32 |
| Book Value Per Share | Rs 198.2 |
| Dividend Yield | 0.55% |
Concord Biotech (CONCORDBIO) fundamental metrics show P/E 52.36x, P/B 6.95x, ROE 13.54%, ROCE 18.04%. Read together, these ratios describe the company’s position rather than a recommendation.
Concord Biotech has a market capitalisation of Rs 13,666.01 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 52.36x, P/B at 6.95x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 13.54% and ROCE of 18.04%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 26.32, book value per share of Rs 198.2, dividend yield of 0.55%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.74x, median ROE of 11.23%, median ROCE of 13.17%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 52.36x |
| Benchmark Median P/E | 30.74x |
| Benchmark Average P/E | 43.3x |
| Benchmark P/E Range | 3.21x to 577.05x |
| Company P/B Ratio | 6.95x |
| Benchmark Median P/B | 2.71x |
| Benchmark Average P/B | 3.99x |
| Company ROE | 13.54% |
| Benchmark Median ROE | 11.23% |
| Benchmark Average ROE | 9.85% |
| Company ROCE | 18.04% |
| Benchmark Median ROCE | 13.17% |
| Benchmark Average ROCE | 12.81% |
| Company Market Capitalisation | Rs 13,666.01 crore |
| Benchmark Median Market Cap | Rs 696.43 crore |
| Benchmark Average Market Cap | Rs 13,492.66 crore |
Concord Biotech (CONCORDBIO) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Concord Biotech (CONCORDBIO) has a P/E ratio of 52.36x, which is above the benchmark median of 30.74x, a difference of +70.33%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Concord Biotech (CONCORDBIO) has a ROE of 13.54%, which is above the benchmark median of 11.23%, a difference of +20.57%. Concord Biotech (CONCORDBIO) has a ROCE of 18.04%, which is above the benchmark median of 13.17%, a difference of +36.98%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,18,204.09 | 34.91 | 4.88 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,40,780 | 86.02 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,73,828.11 | 82.48 | 9.53 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,520.92 | 25.79 | 4.32 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,304.32 | 105.74 | 20.5 | 18.31 | 18.2 |
Concord Biotech (CONCORDBIO) has a P/E ratio of 52.36x compared with the displayed peer median of 82.48x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 13.54% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 18.04% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Concord Biotech (CONCORDBIO) has a market capitalisation of Rs 13,666.01 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Concord Biotech
- The stock fell 7.65% from a previous close of Rs 1,378.35 to Rs 1,272.9, a decline of Rs 105.45 per share.
- The stock has moved between a day low of Rs 1,265.3 and a day high of Rs 1,339.95.
- The P/E of 52.36 compares with the Pharmaceuticals & Drugs industry median of 30.74.
- ROE of 13.54% and ROCE of 18.04% compare with industry medians of 11.23% and 13.17%.
- Market capitalisation of Rs 13,666.01 crore compares with the industry median of Rs 696.43 crore.
About Concord Biotech
Concord Biotech is a listed company classified under the Pharmaceuticals & Drugs industry within the Healthcare sector. It trades under the symbol CONCORDBIO and is categorised as a Mid Cap stock with a market capitalisation of Rs 13,666.01 crore. Within the Pharmaceuticals & Drugs industry, it is one of 199 companies in the benchmark group, and its market capitalisation is above the group median. The company reports earnings per share of Rs 26.32 and book value per share of Rs 198.2, and it shows a dividend yield of 0.55.
Track Concord Biotech Share Price on Univest
Use Concord Biotech (CONCORDBIO) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Readers who want to follow the Concord Biotech Share Price can use Univest to track the live share price, key fundamental ratios, 52-week levels and wider market insights in one place. Univest also lets users compare the company with its industry peers and review sector benchmarks, which helps place any single-session move in context. Check the Univest stock page for Concord Biotech for the latest figures.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Concord Biotech share price falling today?
Ans. The stock traded at Rs 1,272.9 against a previous close of Rs 1,378.35, a decline of 7.65% in the latest session. The P/E ratio of 52.36 and P/B ratio of 6.95 frame the valuation after the move.
What is the Concord Biotech share price today?
Ans. The Concord Biotech share price was Rs 1,272.9 as of 28 October 2026. That compares with a previous close of Rs 1,378.35, a fall of Rs 105.45 per share or 7.65% in the session.
What is the market capitalisation of Concord Biotech?
Ans. Concord Biotech has a market capitalisation of Rs 13,666.01 crore and is categorised as a Mid Cap company. That is above the Pharmaceuticals & Drugs median market capitalisation of Rs 696.43 crore.
What are the P/E and P/B ratios of Concord Biotech?
Ans. Concord Biotech has a P/E ratio of 52.36 and a P/B ratio of 6.95. The industry median P/E is 30.74 and the median P/B is 2.71, so the P/E sits above and the P/B sits above the benchmark.
What are the ROE and ROCE of Concord Biotech?
Ans. Concord Biotech reports return on equity of 13.54% and return on capital employed of 18.04%. The industry medians are 11.23% for ROE and 13.17% for ROCE, so ROE is above its median and ROCE is above its median.
What is the EPS and book value of Concord Biotech?
Ans. Concord Biotech has earnings per share of Rs 26.32 and a book value per share of Rs 198.2. EPS shows earnings attributable to each share, while book value shows the accounting net worth per share.
Does Concord Biotech pay a dividend?
Ans. The dividend yield for Concord Biotech is 0.55%, which shows the historical payout relative to the current share price of Rs 1,272.9. Dividend yield is past and current data, not a guarantee of future payouts.
Which sector does Concord Biotech belong to?
Ans. Concord Biotech belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. Its benchmark covers 199 companies, with a median P/E of 30.74 and a median market capitalisation of Rs 696.43 crore for the group.
How does Concord Biotech compare with its peers?
Ans. Peers such as Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals report P/E ratios between 25.79 and 105.74. Concord Biotech has a P/E of 52.36, ROE of 13.54% and ROCE of 18.04%.
